|
|
|
Insider
Information: |
Gordon Carl L |
Relationship: |
Director, 10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
5,900 |
|
Indirect Shares
|
35,147,503 |
|
|
Direct
Value |
$9,617 |
|
|
Indirect Value
|
$618,034,826 |
|
|
Total
Shares |
35,153,403 |
|
|
Total
Value |
$618,044,443 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
6
|
0
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
5
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
3.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Acadia Pharmaceuticals Inc |
ACAD |
Director |
2004-06-02 |
0 |
2005-04-20 |
1,395,612 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2005-12-02 |
0 |
2005-12-02 |
1,100,000 |
Premium* |
|
Pacira Pharmaceuticals, Inc. |
PCRX |
Director |
|
0 |
2011-02-08 |
2,828,941 |
Premium* |
|
Amarin Corp Plc |
AMRN |
Director |
2011-02-28 |
0 |
2012-09-04 |
5,700 |
Premium* |
|
Acceleron Pharma Inc |
XLRN |
Director |
|
0 |
2013-09-18 |
8,006 |
Premium* |
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2016-05-11 |
0 |
2016-05-11 |
2,662,180 |
Premium* |
|
Selecta Biosciences Inc |
SELB |
Director, 10% Owner |
|
0 |
2016-06-27 |
1,825,415 |
Premium* |
|
X4 Pharmaceuticals Inc |
XFOR |
Director, 10% Owner |
2017-11-20 |
0 |
2017-11-20 |
1,868,966 |
Premium* |
|
Armo Biosciences Inc |
ARMO |
Director |
2018-01-30 |
0 |
2018-06-22 |
0 |
Premium* |
|
Alector, Inc. |
ALEC |
Director, 10% Owner |
2019-02-11 |
0 |
2019-02-11 |
203,200 |
Premium* |
|
Turning Point Therapeutics, Inc. |
TPTX |
Director |
2019-04-22 |
0 |
2019-04-22 |
2,027,550 |
Premium* |
|
Prevail Therapeutics Inc. |
PRVL |
Director, 10% Owner |
|
0 |
2021-01-22 |
0 |
Premium* |
|
Keros Therapeutics, Inc. |
KROS |
Director |
2020-04-13 |
0 |
2020-04-13 |
1,119,812 |
Premium* |
|
Oric Pharmaceuticals, Inc. |
ORIC |
Director |
2020-04-24 |
0 |
2021-03-30 |
2,212,571 |
Premium* |
|
Adicet Bio, Inc |
ACET |
|
2023-06-01 |
5,900 |
2024-01-25 |
2,930,527 |
Premium* |
|
Kinnate Biopharma Inc. |
KNTE |
Director, 10% Owner |
2020-12-07 |
0 |
2024-04-03 |
0 |
Premium* |
|
Terns Pharmaceuticals, Inc. |
TERN |
Director, 10% Owner |
2021-02-09 |
0 |
2022-12-23 |
7,619,135 |
Premium* |
|
Disc Medicine, Inc |
IRON |
Director, 10% Owner |
|
0 |
2021-02-05 |
5,826,224 |
Premium* |
|
Theseus Pharmaceuticals, Inc. |
THRX |
Director, 10% Owner |
2021-10-12 |
0 |
2024-02-14 |
0 |
Premium* |
|
Arrivent Biopharma, Inc. |
AVBP |
Director, 10% Owner |
2024-01-30 |
0 |
2024-01-30 |
1,513,664 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
100 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ACET |
Adicet Bio, Inc |
Director |
|
2021-02-12 |
4 |
A |
$13.00 |
$6,816,537 |
I/I |
524,349 |
396,657 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-11 |
4 |
AS |
$33.04 |
$1,934,525 |
I/I |
(58,551) |
2,707,166 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-12 |
4 |
AS |
$30.29 |
$2,741,881 |
I/I |
(90,521) |
2,616,645 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-15 |
4 |
AS |
$29.14 |
$2,599,579 |
I/I |
(89,210) |
2,527,435 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-16 |
4 |
AS |
$27.72 |
$1,146,305 |
I/I |
(41,353) |
2,486,082 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-17 |
4 |
AS |
$28.43 |
$534,200 |
I/I |
(18,790) |
2,467,292 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-18 |
4 |
AS |
$28.03 |
$169,834 |
I/I |
(6,059) |
2,461,233 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-19 |
4 |
AS |
$26.47 |
$563,149 |
I/I |
(21,275) |
2,439,958 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-22 |
4 |
AS |
$26.47 |
$203,104 |
I/I |
(7,673) |
2,432,285 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-23 |
4 |
AS |
$24.32 |
$97,085 |
I/I |
(3,992) |
2,428,293 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-24 |
4 |
AS |
$24.80 |
$817,383 |
I/I |
(32,959) |
2,395,334 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-25 |
4 |
AS |
$24.70 |
$1,272,618 |
I/I |
(51,523) |
2,343,811 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-26 |
4 |
AS |
$23.88 |
$664,246 |
I/I |
(27,816) |
2,315,995 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-29 |
4 |
AS |
$23.31 |
$1,761,187 |
I/I |
(75,555) |
2,240,440 |
0 |
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Director |
|
2021-03-30 |
4 |
AS |
$23.93 |
$666,905 |
I/I |
(27,869) |
2,212,571 |
0 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2021-10-12 |
4 |
A |
$0.00 |
$0 |
I/I |
16,213,668 |
436,650 |
0 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2021-10-12 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
499,150 |
2.25 |
- |
|
ACET |
Adicet Bio, Inc |
Director |
|
2021-12-10 |
4 |
A |
$14.00 |
$2,999,990 |
I/I |
214,285 |
242,285 |
0 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-11 |
4 |
B |
$9.81 |
$89,319 |
I/I |
8,500 |
16,348,018 |
2.25 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-12 |
4 |
B |
$10.06 |
$190,104 |
I/I |
18,897 |
16,366,915 |
2.25 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-13 |
4 |
B |
$9.43 |
$163,328 |
I/I |
17,320 |
16,384,235 |
2.25 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-19 |
4 |
B |
$9.97 |
$114,864 |
I/I |
11,521 |
16,395,756 |
2.25 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-20 |
4 |
B |
$9.95 |
$348,250 |
I/I |
35,000 |
16,430,756 |
2.25 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-21 |
4 |
B |
$9.97 |
$1,115,603 |
I/I |
111,896 |
16,542,652 |
2.25 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2022-02-11 |
4 |
B |
$10.22 |
$1,594,320 |
I/I |
156,000 |
3,469,330 |
2.1 |
- |
|
100 Records found
|
|
Page 3 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|